Scientific advances – Intravenous artesunate for severe Malaria in Travelers, EuropeArchived
This study describes the outcome of 25 travellers with severe malaria who returned from malaria-endemic regions and were treated at 7 centres in Europe with intravenous artesunate. Among these 25 patients, one child and 24 adults (mean ± SD age 44.1 ± 16.1 years), 10 patients received the dosing regimen for artesunate initially recommended by WHO and 11 received artesunate, 2.4 mg/kg/dose.
Protracted rheumatic manifestations in travelersArchived
This paper describes a small retrospective observational study of Israeli travellers presenting to a tropical medicine clinic with a history of prolonged (4 weeks), non-traumatic arthralgia or arthritis over a 5 year period.
Artesunate versus quinine in the treatment of severe falciparum malaria malaria in African children (AQUAMAT): an open-label, randomized trialArchived
This paper describes the results of an open-label randomized trial, comparing the use of artesunate and quinine for the treatment of severe Plasmodium falciparum malaria in children in 11 African countries.